Floatz logo

LISPRO-PH20 COMPONENT RHUPH20

Multiple Sclerosis

Hoffmann-La Rocheprotein_peptidePhase 1Active
CC
40/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
65/ 100

Competitive context

182 Active assets in the Multiple Sclerosis cohort.

Asset / SponsorPhaseRating
Cladribine
University Hospital, Strasbourg, France
Phase 4BBB
Nabiximols
Jazz Pharmaceuticals
Phase 4BBB
Teriflunomide
Sanofi
Phase 4BBB
Fampridine
MGH Institute of Health Professions
Phase 4BBB
Ocrevus
Polpharma Biologics International AG
Phase 4BBB

View all 50 →

Same molecule, other indications

LISPRO-PH20 COMPONENT RHUPH20 is also rated in:

hereditary angioedemaDormant
B
Indicative ·
62 / 100
View asset →
smoldering plasma cell myelomaDormant
B
Indicative ·
59 / 100
View asset →
melanomaDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →